Nursing Elites

1. How should rifampin most likely be administered to a patient diagnosed with tuberculosis?

• A. Orally, with food
• B. Orally, on an empty stomach
• C. Intramuscularly
• D. Intravenously, as a bolus

Correct answer: A

Rationale: Rifampin is typically administered orally, and it is recommended to be taken with food to enhance its absorption and reduce gastrointestinal side effects. Administering rifampin intramuscularly or intravenously is not the standard route of administration for this medication used in tuberculosis treatment.

2. A patient presents with a chronic cough, night sweats, and weight loss. A chest X-ray reveals upper lobe cavitary lesions. Which of the following is the most likely diagnosis?

• A. Tuberculosis
• B. Pneumonia
• C. Lung cancer
• D. Sarcoidosis

Correct answer: A

Rationale: The correct answer is A: Tuberculosis. Cavitary lesions in the upper lobes are classic findings seen in tuberculosis. This infectious disease commonly presents with symptoms such as chronic cough, night sweats, and weight loss. Pneumonia (Choice B) typically does not present with cavitary lesions on chest X-ray. Lung cancer (Choice C) may present with similar symptoms but is less likely to cause cavitary lesions in the upper lobes. Sarcoidosis (Choice D) usually presents with bilateral hilar lymphadenopathy and non-caseating granulomas, different from the cavitary lesions described in the case.

3. A patient with a diagnosis of renal failure is being treated with epoetin alfa (Epogen). Frequent assessment of which of the following laboratory values should be prioritized before and during treatment?

• A. AST
• B. C-reactive protein
• C. CBC
• D. ALT

Correct answer: A

Rationale: The correct answer is AST. Epoetin alfa is a medication used to treat anemia associated with chronic renal failure. During treatment with epoetin alfa, it is crucial to monitor AST levels as this medication can potentially lead to liver toxicity. Assessing AST levels before and throughout treatment helps in early detection of any liver abnormalities. C-reactive protein is not specifically related to the use of epoetin alfa in renal failure. While CBC (Complete Blood Count) monitoring is essential during treatment with epoetin alfa to evaluate the response to therapy, prioritizing AST assessment is more critical due to the potential for liver toxicity. ALT monitoring is also important but AST is prioritized in this scenario.

4. A patient is prescribed medroxyprogesterone acetate (Provera) for the treatment of endometriosis. What should the nurse include in the patient teaching?

• A. Take the medication with food to prevent nausea.
• B. Take the medication at the same time each day to maintain consistent hormone levels.
• C. Avoid prolonged sun exposure while taking this medication.
• D. Discontinue the medication if side effects occur.

Correct answer: B

Rationale: The correct answer is to take the medication at the same time each day to maintain consistent hormone levels and effectiveness. This is crucial for the drug to work optimally. Choice A is incorrect because medroxyprogesterone acetate does not necessarily need to be taken with food to prevent nausea. Choice C is not directly related to the medication's administration and is not a common teaching point for this drug. Choice D is incorrect as discontinuing the medication abruptly can lead to adverse effects and is not recommended without consulting a healthcare provider.

5. A male patient is receiving testosterone therapy for hypogonadism. What adverse effect should the nurse be most concerned about?

• A. Increased risk of breast cancer
• B. Increased risk of liver dysfunction
• C. Increased risk of cardiovascular events
• D. Increased risk of prostate cancer

Correct answer: C

Rationale: The correct answer is C: Increased risk of cardiovascular events. Cardiovascular events such as stroke and myocardial infarction are the most concerning adverse effects of testosterone therapy, especially in older patients. Choice A, increased risk of breast cancer, is not a common adverse effect of testosterone therapy in males. Choice B, increased risk of liver dysfunction, is a potential adverse effect but is not the most concerning. Choice D, increased risk of prostate cancer, is a consideration in patients with a history of prostate cancer or those with prostate carcinoma, not typically in patients receiving testosterone therapy for hypogonadism.

Similar Questions